Suchen
Barinthus Biotherapeutics PLC
BRNSZur Watchlist hinzufügen
0.640USD
-0.020-3.02%
Handelsschluss 07/01, 16:00（ET）Kurse um 15 Minuten verzögert
26.15MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Barinthus Biotherapeutics PLC Unternehmen
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Barinthus Biotherapeutics PLC Informationen
BörsenkürzelBRNS
Name des UnternehmensBarinthus Biotherapeutics PLC
IPO-datumApr 30, 2021
CEOEnright (William J)
Anzahl der mitarbeiter105
WertpapierartDepository Receipt
GeschäftsjahresendeApr 30
AddresseUnit 6-10, Zeus Building, Rutherford Avenue
StadtDIDCOT
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited Kingdom
PostleitzahlOX11 0DF
Telefon441865818808
Websitehttps://www.barinthusbio.com/
BörsenkürzelBRNS
IPO-datumApr 30, 2021
CEOEnright (William J)
Führungskräfte von Barinthus Biotherapeutics PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
640.64K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Ms. Karen T. Dawes
Ms. Karen T. Dawes
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Joseph C. Scheeren
Dr. Joseph C. Scheeren
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Leon Hooftman, M.D.
Dr. Leon Hooftman, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Geoffrey Lynn
Dr. Geoffrey Lynn
Chief Scientific Officer
Chief Scientific Officer
640.64K
--
Mr. Robin Wright
Mr. Robin Wright
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
48.26K
--
Dr. Pierre A. Morgon, Pharm.D.
Dr. Pierre A. Morgon, Pharm.D.
Non-Executive Independent Director
Non-Executive Independent Director
10.51K
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
3.00K
--
Mr. William J. (Bill) Enright
Mr. William J. (Bill) Enright
Chief Executive Officer, Principal Financial Officer, Director
Chief Executive Officer, Principal Financial Officer, Director
--
--
Dr. Alex Hammacher
Dr. Alex Hammacher
Non-Executive Director
Non-Executive Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Barinthus Biotherapeutics PLC?
Die fünf größten Anteilseigner von Barinthus Biotherapeutics PLC sind: Dr. Geoffrey Lynn
Wie viele Institutionen halten Anteile an Barinthus Biotherapeutics PLC (BRNS)?
Mit Stand vom 2026Q1 halten 32 Institutionen Anteile an Barinthus Biotherapeutics PLC, mit einem Gesamtmarktwert von etwa 16.70M, was 40.87% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -1943125.00 gestiegen.